[Hyperthermic immunotherapy was effective in 3 CR cases as the standard treatments had no effects or could not be enforced].
We treated 1, 225 advanced or recurrent cancer patients with hyperthermia or immunotherapy (2005/7-2010/12). We had 174 (14.7%)clinical benefit cases (CR, PR and long SD) including 32 complete response (CR) cases. CASE 1: A 63-year-old male, rectal cancer, post operative recurrence with MRSA abscess located in abdomen. He was treated with dendritic cell therapy and hyperthermia. He showed a CR. CASE 2: A 62-year-old female, ovarian cancer, post operative recurrence. She was treated with standard chemotherapy, but she showed a PD. Then she was treated with dendritic cell therapy and hyperthermia. She showed a CR. CASE 3: A 46-year-old female, lung cancer, postoperative recurrence. She was treated with standard chemotherapy and molecular target therapy, but she showed a PD. Then she was treated with dendritic cell therapy and hyperthermia. She showed a CR.
Osaka Cancer Immuno- Chemotherapy Center.
Hiroko
H
Takeda
Takashi
T
Takeda
Shohgo
S
Kobayashi
Tsutomu
T
Takeda
D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction